RecruitingPhase 1NCT05865470

Age-dependent Effects of Smoked and Oral Delta-9-THC

Sex- and AGE-dependent Effects of Smoked and Oral Delta-9-THC


Sponsor

University of California, Los Angeles

Enrollment

103 participants

Start Date

Apr 30, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria7

  • Male or non-pregnant female aged 18-65 years according to the below criteria: EMERGING ADULTS: 18-25 years of age (+/- one year) MIDDLE-AGED ADULTS: 35-45 years of age (+/- one year) LATE MIDDLE-AGED ADULTS: 55-65 years of age (+/- one year)
  • Report weekly-monthly use of cannabis (with primary mode of use via inhalation) over the past 6 months prior to screening
  • Not currently seeking treatment for their cannabis use
  • No reported clinically significant adverse effects with cannabis use
  • Have a Body Mass Index from 18.5 - 34kg/m2
  • Able to perform all study procedures
  • FEMALES: Currently practicing an effective form of birth control if pre-menopausal

Exclusion Criteria14

  • Meeting DSM-5 (Diagnostic and Statistical Manual of Mental Disorders-5) criteria for any substance use disorder other than nicotine and mild cannabis use disorder
  • Report using other illicit drugs in the prior 4 weeks
  • Evidence of severe psychiatric illness (e.g. mood disorder with functional impairment or suicide risk, schizophrenia) or medical condition (i.e., hypertension) judged by the study physician (and PI to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent.
  • Current predominant licit use of medical cannabis
  • Current use of prescription or regular use of over the counter medications (with the exception of hormonal contraceptives and hormone replacement therapy). Current use of herbal supplements that may affect study outcomes or interact with study drug (i.e., St Johns wort, kava, L-tryptophan, melatonin)
  • If medical history, physical and psychiatric examination, or laboratory tests performed during the screening process are not within the normal range and / or reveal any significant illness (e.g., hypertension) as judged by the study physician and to put the participant at greater risk of experiencing adverse events due to completion of study procedures
  • Current pain
  • Pregnancy is exclusionary due to the possible effects of the study medication on fetal development
  • History of an allergic reaction or adverse reaction to cannabis is exclusionary.
  • Currently enrolled in another research protocol
  • Not using a contraceptive method (hormonal or barrier methods)
  • The evaluating physician reviews all medical assessments along with medical history. Any disorders that might make cannabis administration hazardous are exclusionary.
  • Intolerance to lactose and sesame (ingredients in the oral THC preparation)
  • Insensitivity to the Cold Pressor Test

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGCannabis

smoked cannabis

DRUGDronabinol

Oral delta-9-THC

DRUGSmoked Placebo

Placebo Cannabis

DRUGOral Placebo

Oral Placebo


Locations(1)

UCLA Center for Cannabis and Cannabinoids

Los Angeles, California, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05865470


Related Trials